MedTrace Logo

Using the Ending Self-Stigma Intervention to Reduce Internalized Stigma Among People Living With HIV Who Use Substances

NCT05704764 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2025-07-20

No results posted yet for this study

Summary

The goal of this clinical trial is to test an intervention to reduce stigma among people living with HIV who use opioids and cocaine. The main question it aims to answer is:

\- Does reducing internalized stigma about HIV and/or drug use lead to improved HIV care outcomes?

After a year spent adapting an existing intervention to be applied specifically among people living with HIV who use substances, 70 participants will be randomized to receive either treatment-as-usual or the newly adapted intervention. The intervention itself will consist of five one-on-one sessions with a trained interventionist to discuss and work through the stigmas people commonly associate with HIV and/or substance use.

Conditions

  • HIV
  • Stigma, Social
  • Substance Use

Interventions

BEHAVIORAL

Ending Self Stigma for Persons living with HIV and Use Substances

One-on-one intervention based on principles of cognitive behavioral therapy and social cognitive theory designed to reduce internalized stigma related to HIV and/or drug use.

Sponsors & Collaborators

  • University of Maryland

    collaborator OTHER

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • Johns Hopkins University

    collaborator OTHER

  • Friends Research Institute, Inc.

    lead OTHER

Principal Investigators

  • Jesse B Fletcher, Ph.D. · Friends Research Institute, Inc.

  • Alicia Lucksted, Ph.D. · University of Maryland

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-17
Primary Completion
2026-03-31
Completion
2026-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05704764 on ClinicalTrials.gov